Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00045799 | Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill | PHASE3 | COMPLETED | 354 | — | — | May 1, 2002 | May 1, 2003 | Nov 25, 2019 | 58 | United States |
| Arm | Type | Description |
|---|---|---|
| Omeprazole sodium bicarbonate immediate release PWD/FS | EXPERIMENTAL | - |
| Cimetidine IV | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Omeprazole sodium bicarbonate immediate release PWD/FS | DRUG | - |
| Cimetidine IV | DRUG | - |
Patients will be included in the trial if they meet all of the following criteria: 1. An adult or adolescent (greater than or equal to 16 years of age) male or non-pregnant female requiring mechanical ventilation for greater than or equal to 48 hours. 2. An anticipated ICU stay of greater than or e...